Video

Q&A With Paul Hudson of AstraZeneca US: ADA Meeting Provides Unique Look at Diabetes Field

Author(s):

With more than 10000 people in Boston for the American Diabetes Association's Scientific Sessions the event provides a chance for some of the top minds in the field to share information.

With more than 10000 people in Boston for the American Diabetes Association's Scientific Sessions the event provides a chance for some of the top minds in the field to share information.

Paul Hudson, President of AstraZeneca US discussed some of the areas of focus of the meeting which was held in Boston this year. Hudson said topics discussed include the latest technology and medicine as well as ways to control costs so patients can afford the treatment they need.

Related Videos
Ben Samelson-Jones,Ben Samelson-Jones, MD, PhD: Validating Long-Term Safety of Hemophilia AAV Gene Therapy MD, PhD: Validating Long-Term Safety of Hemophilia AAV Gene Therapy
Françoise Bernaudin, MD: A Decade of Follow-up Reveals allo-SCT Superiority Over SOC for Sickle Cell Anemia
Achieving Quick Responses in Sickle Cell Anemia With Early, Appropriate Hydroxyurea Dosing, with Abena Appiah-Kubi, MD, MPH
Steven W. Pipe, MD: Fitusiran With Anti-Thrombin Modulation Yields Effective Bleed Control, Reduces Infusions
Caroline Piatek, MD: Improving Patient-Reported Outcomes in PNH With Danicopan Add-on Therapy
Haydar Frangoul, MD: Preventing VOCs in People With Sickle Cell Disease With Exa-Cel Gene Editing Therapy
Jörn Schattenberg, MD | Credit: Novo Nordisk
Diabetes Dialogue: Diabetes Tech Updates from November 2024 | Image Credit: HCPLive
Jörn Schattenberg, MD | Credit: Novo Nordisk
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
© 2024 MJH Life Sciences

All rights reserved.